Succimer treatment and calcium supplementation reduce tissue lead in suckling rats.
The effect of combined treatment with meso-2,3-dimercaptosuccinic acid (DMSA) and calcium supplementation in reducing lead absorption and enhancing lead elimination was evaluated in suckling rats under two experimental conditions: during ongoing oral lead exposure (lead acetate, 2 mg Pb kg(-1) day(-1), total dose 16 mg Pb kg(-1)) or after lead exposure (72 h after a 2-day lead exposure, total dose 12 mg Pb kg(-1) s.c.). The artificial feeding method was used for calcium supplementation, with 6% Ca (as CaHPO(4)) suspension in cow's milk to increase the daily calcium intake about three times above control values. Artificial feeding lasted for 7 h a day over eight consecutive days. During this period DMSA was administered on 6 days twice a day (0.5 mmol kg(-1) day(-1) p.o.). At the end of the experiments, Pb, Ca and Zn in the carcass and Pb, Fe and Cu in the liver, kidneys and brain were analysed by atomic absorption spectrometry. Calcium supplementation during lead exposure reduced tissue lead but had no effect when applied after lead exposure, and DMSA administered either during or after lead exposure lowered the tissue lead. Combined treatment during ongoing lead exposure caused a greater reduction in tissue lead than either DMSA or calcium treatment alone. When administered after lead exposure, it had no advantage over DMSA treatment alone but did not impair its efficacy. Combined treatment had no influence on growth and did not seriously disturb essential element status. It is concluded that calcium supplementation could be applied during DMSA therapy, when indicated.
Marija Varnai
Veda
V
Mineral Metabolism Unit, Institute for Medical Research and Occupational Health, Zagreb, Croatia. vvarnai@imi.hr
Piasek
Martina
M
Blanusa
Maja
M
Matek Sarić
Marijana
M
Juresa
Dijana
D
Kostial
Krista
K
D000818:Animals; D000833:Animals, Suckling; D002136:Calcium, Dietary / Q000008:administration & dosage*; D002614:Chelating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D007854:Lead / Q000032:analysis / Q000493:pharmacokinetics* / Q000633:toxicity; D007855:Lead Poisoning / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013054:Spectrophotometry, Atomic; D004113:Succimer / Q000494:pharmacology* / Q000627:therapeutic use; D014018:Tissue Distribution; D015032:Zinc / Q000032:analysis
D002136:Calcium, Dietary; D002614:Chelating Agents; D007854:Lead; D004113:Succimer; D015032:Zinc